An interventional study of Polylevolactic Acid Injection and 1565nm Non-ablative Fractional Laser in Striae Distensae, sponsored by Xijing Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment
39 studies on the registry are indexed under Striae Distensae; 6 are open to participants now.
This study's planned enrollment of 30 is close to the median of 28 across 38 interventional studies indexed under Striae Distensae.
Browse Striae Distensae studies →Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Polylevolactic Acid Injection in SD
Device: Polylevolactic Acid Injection
1565nm Non-ablative Fractional Laser treatment in SD
Device: 1565nm Non-ablative Fractional Laser
Polylevolactic Acid injection combined with 1565nm Non-ablative Fractional Laser treatment in SD
Device: Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser
The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
combination of the two treatments described above
The treatment effect is judged by color, area, concavity and convexity, and skin elasticity
* Color: Ranked in order as follows: Purple red pink skin color, no change 0 point, 1 point added for each shade subtracted; * Area: 0 point: no change, 1 point: slightly improved, 2 points: significantly improved, 3 points: basically invisible; * Bump sensation: 0 point: no change, 1 point: slightly improved, 2 points: significantly improved, 3 points: bump basically eliminated; * Skin elasticity: 0 point: no change, 1 point: slightly improved, 2 points: significantly improved, 3 points: very satisfied; The total score of 6-12 points is basically cured; A total score of 3-5 points is significant; Effective with a total score of 1-2; A total score ≤ 1 is invalid. Total effective rate of treatment=(basically cured+significantly effective+effective)/total number of cases × 100%. Higher scores mean a better outcome.
Time frame: 4months
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital